We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
Read MoreHide Full Article
Eli Lilly and Company’s (LLY - Free Report) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. together announced the availability of a new drug - Galliprant (grapiprant tablets) to the veterinarians for the management of pain and inflammation associated with canine osteoarthritis (OA).
Lilly’s share price has declined 8.4% in the past one year compared with the Zacks classified Large Cap Pharmaceuticals industry’s fall of 2.1%.
Coming back to the release, Galliprant - the first piprant approved for use in veterinary medicine is now available to veterinarians for once-daily use in dogs with OA. Also, it can be used in patients as young as 9 months. Osteoarthritis is incurable disease and is one of the most common causes of chronic pain in dogs. However, if diagnosed early the pain and inflammation can be controlled enabling the arthritic dogs to have an improved quality of life.
Elanco has exclusive rights for developing, manufacturing and marketing Galliprant globally, and it co-promotes the product with Aratana in the U.S. Lilly’s Elanco makes parasiticides, pain and dermatology medicines for food animals as well as companion animals. In January 2017, the division acquired German drugmaker Boehringer Ingelheim’s Vetmedica U.S. pet vaccines unit along with a fully integrated manufacturing and R&D site for $885 million.
The deal diversified Elanco's U.S. companion animal portfolio by complementing its offerings for dogs and cats. Notably, Lilly bought the animal-health division of Novartis (NVS - Free Report) in early 2015, which strengthened the Elanco division of the company.
Lilly currently carries a Zacks Rank #2 (Buy). Another favorably ranked stock in the health care sector includes Anika Therapeutics Inc. (ANIK - Free Report) which sports a Zacks Rank #2 (Buy), Enzo Biochem carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 39.5% in the past one year.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
Eli Lilly and Company’s (LLY - Free Report) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. together announced the availability of a new drug - Galliprant (grapiprant tablets) to the veterinarians for the management of pain and inflammation associated with canine osteoarthritis (OA).
Lilly’s share price has declined 8.4% in the past one year compared with the Zacks classified Large Cap Pharmaceuticals industry’s fall of 2.1%.
Coming back to the release, Galliprant - the first piprant approved for use in veterinary medicine is now available to veterinarians for once-daily use in dogs with OA. Also, it can be used in patients as young as 9 months.
Osteoarthritis is incurable disease and is one of the most common causes of chronic pain in dogs. However, if diagnosed early the pain and inflammation can be controlled enabling the arthritic dogs to have an improved quality of life.
Elanco has exclusive rights for developing, manufacturing and marketing Galliprant globally, and it co-promotes the product with Aratana in the U.S.
Lilly’s Elanco makes parasiticides, pain and dermatology medicines for food animals as well as companion animals. In January 2017, the division acquired German drugmaker Boehringer Ingelheim’s Vetmedica U.S. pet vaccines unit along with a fully integrated manufacturing and R&D site for $885 million.
The deal diversified Elanco's U.S. companion animal portfolio by complementing its offerings for dogs and cats. Notably, Lilly bought the animal-health division of Novartis (NVS - Free Report) in early 2015, which strengthened the Elanco division of the company.
Eli Lilly and Company Price
Eli Lilly and Company Price | Eli Lilly and Company Quote
Zacks Rank & Key Pick
Lilly currently carries a Zacks Rank #2 (Buy). Another favorably ranked stock in the health care sector includes Anika Therapeutics Inc. (ANIK - Free Report) which sports a Zacks Rank #2 (Buy), Enzo Biochem carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 39.5% in the past one year.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>